ArticlePloS one2026
Virtual screening of Kocuria oceani AT-1 metabolites as potential maize growth regulators under drought conditions using molecular docking and dynamics simulation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maize is a vital cereal crop, severely affected by environmental factors and climate change. Among abiotic factors, drought stress is considered one of the most detrimental factors limiting plant growth and biomass production. However, the molecular basis of bacterial metabolite-mediated drought tolerance in cereal crops remains poorly understood. The current in silico study aimed to investigate the molecular interactions between Kocuria oceani AT-1 metabolites and the maize UGT706F8 protein, using molecular docking and dynamics simulation analyses. The molecular interactions between bacterial metabolites and the UGT706F8 protein (glycosyltransferase enzyme, PDB ID 7Q3S) from Zea mays L. were evaluated. The in silico docking findings revealed a favorable binding affinity between bacterial metabolites and the target protein, indicating stable molecular interactions at the protein active site. Specifically, 4-tetradecanoyl-2,6-piperazinedione, and 3-benzylhexahydropyrrolo(1,2-a)pyrazine-1,4-dione displayed binding energies of -7.5 ± 0.33 and -8.5 ± 0.36 kcal/mol against the target protein, respectively. Under identical docking parameters, the known plant growth regulators (indole acetic acid and abscisic acid) yielded binding energies of -6.6 ± 0.34 and -5.8 ± 0.32 kcal/mol, respectively. Re-docking of the native uridine-5-diphosphate (UDP) ligand yielded a Root Mean Square Deviation (RMSD) of 0.9 Å, validating the reliability of the docking procedure. Additionally, molecular dynamics simulation (200 nanoseconds) outcomes supported these predictions, indicating stable molecular interactions and structural integrity of ligand-protein complexes, with ligand RMSD values remaining between 2 and 3 Å. The formation of hydrogen bonding (an average of 2.4 ± 0.6 and 2.1 ± 0.5, respectively), hydrophobic interactions, and stable Solvent-Accessible Surface Area (SASA) profiles (ranging between 19,000-22,000 Å2 and 19,000-21,000 Å2, respectively) suggest the stability of complexes. Moreover, Molecular Mechanics Generalized Born Surface Area (MM-GBSA) outcomes (-102.05 ± 13.96 and -54.86 ± 7.93 kcal/mol, respectively) supported the favorable binding energetics of ligand-protein complexes. These computational outcomes suggest that Kocuria oceani metabolites can establish stable molecular interactions with the UGT706F8 protein, which may influence glycosyltransferase function. Further in vivo experimental validation is required to confirm their predicted maize growth-promoting potential under drought conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.